Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.46 |
| ▸ | MAOB | P27338 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | CALML3 | P27482 | 1/20 | 0.46 |
| ▸ | SDHA | P31040 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 10/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5889328 | 1.00 | MAOA (0.46) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL5217408 | 0.91 | MAOA (0.56) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL5889329 | 0.90 | MAOA (0.46) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL5215887 | 0.90 | MAOA (0.44) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL5216864 | 0.89 | F10 (0.43) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL5218199 | 0.88 | MAOB (0.57) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL5252369 | 0.87 | MAOA (0.41) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL5215173 | 0.87 | MAOA (0.41) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL5219467 | 0.87 | F10 (0.46) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL23833823 | 0.82 | F10 (0.56) | MAOAMAOBLMNAPTGS1CALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101874-B2 | Antimicrobial dihydrothiazine and dihydrothiopyran oxazolidinones | PHARMACIA AND UPJOHN COMPANY (US) | 2006-09-05 | — | — | US | disclosed |
| US-20050143376-A1 | Antimicrobial dihydrothiazine and dihydrothiopyran oxazolidinones | GORDEEV MIKHAIL F (US) | 2005-06-30 | — | — | US | disclosed |
| US-6884813-B2 | Antimicrobial dihydrothiazine and dihydrothiopyran oxazolidinones | PHARMACIA & UPJOHN COMPANY (US) | 2005-04-26 | — | — | US | disclosed |
| US-20030232812-A1 | Antimicrobial dihydrothiazine and dihydrothiopyran oxazolidinones | PHARMACIA & UPJOHN COMPANY | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143376-A1 | Antimicrobial dihydrothiazine and dihydrothiopyran oxazolidinones | DHX35, DHX15, OXA1L | MAOA 3852/4885MAOB 3530/4885LMNA 4838/4885 |
| US-20030232812-A1 | Antimicrobial dihydrothiazine and dihydrothiopyran oxazolidinones | DHX35, ZYX, DHX15 | MAOA 3803/4885MAOB 3725/4885LMNA 4827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.